{"id":20029,"date":"2026-03-27T15:06:16","date_gmt":"2026-03-27T15:06:16","guid":{"rendered":"https:\/\/p-bio.org\/noticias\/biovance-capital-invests-e4-million-in-laigo-bio-and-co-leads-its-oversubscribed-e17-million-seed-round\/"},"modified":"2026-03-27T15:11:55","modified_gmt":"2026-03-27T15:11:55","slug":"biovance-capital-invests-e4-million-in-laigo-bio-and-co-leads-its-oversubscribed-e17-million-seed-round","status":"publish","type":"noticias","link":"https:\/\/p-bio.org\/en\/news\/biovance-capital-invests-e4-million-in-laigo-bio-and-co-leads-its-oversubscribed-e17-million-seed-round\/","title":{"rendered":"Biovance Capital invests \u20ac4 million in Laigo Bio and co-leads its oversubscribed \u20ac17 million seed round"},"content":{"rendered":"\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\t\t
\n\t\t\t\t\t\t\t\t\t\t\"\"\t\t\t\t\t\t\t\t\t\t\t
<\/figcaption>\n\t\t\t\t\t\t\t\t\t\t<\/figure>\n\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

\u2022 Laigo Bio, based in the Netherlands, is developing breakthrough treatments for oncology and autoimmune diseases.<\/i><\/span><\/h3>

\u2022 This deal represents the first international investment of Biovance Capital Fund I, which will also enable the expansion of Laigo Bio into Portugal.<\/i><\/span><\/h3>

\u2022 The company expanded its initial \u20ac11.5 million seed round, announced in December, to \u20ac17 million at this second close, with new investments from Biovance and Kurma Partners.<\/i><\/span><\/h3>
<\/div>

Biovance Capital, Portugal\u2019s leading life sciences venture capital firm, announced today during BIO-Europe Spring in Lisbon that it has invested \u20ac4 million in Dutch biotech company Laigo Bio (\u201cLaigo\u201d), as part of the second close of its \u20ac17 million seed investment round. Biovance co-led this round together with Kurma Partners, alongside a strong line-up of European investors including Angelini Ventures, Curie Capital, Argobio Studio, Eurazeo, Oncode Bridge Fund, ROM Utrecht region, and Cancer Research Horizons. <\/span><\/h3>

Laigo is a biotech company pioneering novel and highly differentiated therapies using its proprietary Surface Removal Targeting Chimeras (SureTAC\u2122) precision membrane protein degradation platform. The proceeds of this financing round will be used to accelerate the development of Laigo\u2019s SureTAC oncology programs towards the clinic, as well as advance its three candidate programs for selected autoimmune and immunology indications, and graft rejection. In addition, with this new investment, Laigo will expand activities in Portugal and recruit world-class local talent. <\/span><\/h3>

Laigo\u2019s proprietary SureTAC platform generates bispecific antibodies that pair an optimal E3 ligase with a disease-causing target protein, stimulating its ubiquitination and degradation with a high degree of specificity. Laigo\u2019s platform allows the development of first-in-class, dual targeted therapies that eliminate disease-driving membrane targets. <\/span><\/h3>

\u201cWe are delighted to announce the first international investment of our fund, and second investment overall, during BIO-Europe Spring in Lisbon. We look forward to supporting Laigo\u2019s growth as its pre-clinical programs advance into the clinic\u201d, said Ricardo Perdig\u00e3o Henriques, PhD, Managing Partner of Biovance Capital, the investment firm co-leading the round. \u201cLaigo has shown that its SureTAC degradation technology results in remarkable in vivo and in vitro efficacy, with a high degree of selectivity and improved toxicity and safety. We at Biovance Capital see phenomenal potential in Laigo\u2019s technology and support its commitment to exploring an ever-evolving universe of new targets, including those currently considered undruggable\u201d, added Jo\u00e3o Incio, MD\/PhD, General Partner of Biovance Capital. <\/span><\/h3>

\u201cThe second close of our seed financing round further validates the potential of our SureTAC platform and its ability to identify first-in-class dual targeted therapies to redefine the treatment of cancer and autoimmune diseases. The additional investment and support from new co-lead investor Biovance Capital, alongside further funding from our existing co-lead investor Kurma Partners, will accelerate our oncology programs towards the clinic and enhance our discovery efforts in autoimmune and immunology. We welcome Dr. Jo\u00e3o Incio to the Board of Directors\u201d, said Matthew Baker, PhD, Chief Executive Officer of Laigo.<\/span><\/h3>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t
About Biovance Capital<\/h6>
Biovance Capital is Portugal\u2019s leading life sciences venture capital firm. The company manages Biovance Capital Fund I, a \u20ac 60 million venture capital fund backed by the European Investment Fund and the European Commission through the Portugal Tech and InvestEU programmes, the largest Portuguese pharmaceutical company BIAL, the national promotional bank Banco Portugu\u00eas de Fomento, private investors such as Caixa Capital, Ageas Pens\u00f5es, Fundo de Pens\u00f5es EDP, in addition to other private investors from the USA and Europe. The fund invests in early-stage drug development companies across Europe, with a special focus on Southern Europe. <\/span><\/h6>
For more information, please visit <\/span>www.www.biovancecapital.com<\/a><\/span><\/h6>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

P-BIO<\/b><\/h3>

March 27, 2026<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t

\n\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

Photo: Biovance Capital<\/i><\/span><\/h3>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t<\/div>\n\t\t","protected":false},"excerpt":{"rendered":"

This deal represents the first international investment of Biovance Capital Fund I, which will also enable the expansion of Laigo Bio into Portugal.<\/p>\n","protected":false},"featured_media":20022,"template":"","meta":{"om_disable_all_campaigns":false,"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"_uf_show_specific_survey":0,"_uf_disable_surveys":false,"footnotes":""},"categoria":[249,392],"class_list":["post-20029","noticias","type-noticias","status-publish","has-post-thumbnail","hentry","categoria-associados","categoria-biovance-capital"],"_links":{"self":[{"href":"https:\/\/p-bio.org\/en\/wp-json\/wp\/v2\/noticias\/20029","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/p-bio.org\/en\/wp-json\/wp\/v2\/noticias"}],"about":[{"href":"https:\/\/p-bio.org\/en\/wp-json\/wp\/v2\/types\/noticias"}],"version-history":[{"count":1,"href":"https:\/\/p-bio.org\/en\/wp-json\/wp\/v2\/noticias\/20029\/revisions"}],"predecessor-version":[{"id":20030,"href":"https:\/\/p-bio.org\/en\/wp-json\/wp\/v2\/noticias\/20029\/revisions\/20030"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/p-bio.org\/en\/wp-json\/wp\/v2\/media\/20022"}],"wp:attachment":[{"href":"https:\/\/p-bio.org\/en\/wp-json\/wp\/v2\/media?parent=20029"}],"wp:term":[{"taxonomy":"categoria","embeddable":true,"href":"https:\/\/p-bio.org\/en\/wp-json\/wp\/v2\/categoria?post=20029"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}